PharmExec1d
Regeneron’s DB-OTO: Overcoming Clinical and Manufacturing Hurdles in Gene Therapy for Hearing Loss
Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses regulatory challenges for DB-OTO, Regeneron’s AAV-based gene therapy for hearing loss.
Dealbreaker on MSN2d
Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio In $286M Deal
Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio ...
1 Dividend Stock Down 30% to Buy and Hold for the Next Decade
Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...
Fierce Pharma3d
In buying cell therapy partner 2seventy bio for $286M, BMS takes full control of Abecma
More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...
Regeneron finalists from Long Island in Washington, D.C., for a shot at up to $250,000 in prize money
Wen is among the 40 finalists heading to Washington, D.C., Thursday to present their projects to panels of experts. The ...
Regeneron, Sanofi presents results from ADEPT Phase 2/3 trial on Dupixent
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the ...
Managed Healthcare Executive7d
Regeneron Canada Reaches New Agreement Deal for Cancer Drug Libtayo
The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in ...
MedCity News4d
Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio in $286M Deal
“We see little to no value in 2seventy for any company looking to build a cell therapy business, as 2seventy already divested its R&D assets to Regeneron and Novo Nordisk, and [Bristol Myers ...